divislab glp-1 novo nordisk relation Reflections on the discovery as a satiety hormone: Implications for obesity therapy and future directions Novo Nordisk's oral GLP-1 drug

However, they differ in a key way: tirzepatide is a dual agonist (GLP-1 and GIP), while retatrutide is a triple agonist (GLP-1, GIP, and GCG)

Warning Letters to Telehealth providers marketing GLP-1 compounded On March 3rd, FDA sent multiple sets of warnings to 30 Telehealth companies offering GLP-1s on their websites warning them to refrain from improperly using a brand when they are not the compounder or claiming equivalency to FDA approved drugs

If we don't meet our proteins needs, our bodies will break down muscle tissue to get what they need

The patients who tend to do well stopping usually have a few things in common: Lost weight quickly (fast responders often do better long-term) Built solid lifestyle changes while taking the medication Work with a complete medical team Gradually taper off instead of stopping cold turkey The Slow-and-Steady Approach Fresh research from Denmark shows that patients who slowly reduced their dose over about nine weeks instead of stopping abruptly had better luck maintaining their weight loss

The real money move